Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$36.75 USD
-2.12 (-5.45%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $36.70 -0.05 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DNTH 36.75 -2.12(-5.45%)
Will DNTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Other News for DNTH
DNTH makes New 52 Week High on September 18
Is DNTH gaining bullish strength? New 52 Week Closing High shows up after advancing 3.76%
Clear Street Initiates Coverage on Dianthus Therapeutics (DNTH) with a 'Buy' Rating | DNTH ...
Fairmount Funds Management LLC Increases Stake in Dianthus Therapeutics Inc
Dianthus Therapeutics (DNTH) Receives a New Rating from Roth MKM